Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas

Figures & data

Table 1. Clinical and histopathologic data (n = 35).

Age	52–79 (mean: 68.3 ± 1.2)
Preoperative PSA value (ng/mL)	5.25–14.95 (mean: 8.19)
Gleason score (prostatectomy)	6–10 (mean: 6.8)
Tumor volume	1 cc–49 cc (8.07 cc ± 1.68 cc)
TNM clinical stage:	T2ab: 14 cases
	T3: 16 cases
	T3b: 5 cases
SP-A and SP-D immunostaining	Uniformly intracytoplasmic in both malignant and nonmalignant areas, intact basal cell layer surrounding the prostatic ductules, acini and HGPIN
Comparison of immunostaining of  malignant and nonmalignant areas
SP-A	80% in prostate adenocarcinomas
	85.3% in non-malignant areas
SP-D	81.8% in prostate adenocarcinoma
	90.6% in non-malignant areas
An intensity score
SP-A	1.20 ± 0.14 in prostate adenocarcinomas
	1.38 ± 0.14 in non-malignant areas
SP-D	1.33 ± 0.13 in prostate adenocarcinoma
	1.72 ± 0.14 in non-malignant areas

Statistically correlated values:

The incidence of both SP-A and SP-D immunostaining decreased in malignant areas in the prostatatectomy tissue samples, there were;

Strong positive correlation between Gleason score and tumor volume (p < 0.01).

Tumor volume correlated negatively with degree of SP-A immunostaining (p < 0.05).

Increase in Gleason score correlated negatively with SP-D immunostaining (p < 0.05).

The mean age correlated negatively with SP-D (p < 0.05).

A positive correlation between the age of patients and PSA values (p < 0.05).

Figure 1. (a) and (b): Immunohistochemical staining of basal cells with SP-A and SP-D proteins (original magnification was 200×).

Figure 2. Strong positive SP-A (a) and SP-D (b) immunostaining particularly in inflammatory sites of non-malignant prostate tissue specimens. Note: Original magnifications for the images was 200×.

Figure 3. Immunohistochemical staining intensity scores. Prostate adenocarcinomas and non-malignant areas in same tissue sections stained with anti SP-A antibody (a) 1+ staining, (c) 2+ staining (e) 3+ staining. Non-malignant areas stained with anti SP-A antibody (b) 1+ staining, (d) 2+ staining (f) 3+ staining. Negative staining (nc1) of prostate adenocarcinoma, negative control staining of non-malignant areas (nc2). Note: Original magnifications of images; (a) 200×, (b) 50×, (c) 100×, (d) 100×, (e) 50×, (f) 50×, nc1; 50×, nc2: 100×.

Figure 4. Immunohistochemical staining intensity scores. Prostate adenocarcinomas and non-malignant areas in same tissue sections stained with anti SP-D antibody (a) 1+ staining, (c) 2+ staining. Non-malignant areas stained with anti SP-D antibody (b) 1+ staining, (d) 2+ staining (e) 3+ staining. Negative control staining (nc). Note: Original magnifications of images; (a) 100×, (b) 50×, (c) 50×, (d) 50×, (e) 100, nc 50×.

Figure 5. (a) and (b) Western blot analysis of SP-A and SP-D in prostate from control and prostate adenocarcinoma. A. Western blot of prostate extracts obtained from noncadenocarcinomas site (NP) and adenocarcinoma field (PA) were probed with antibodies against SP-A (a) and SP-D (b). Note: PA; prostate adenocarcinoma, NP; normal prostate, C; control, NC; negative control.